Fibromyalgia
Conditions
Keywords
Physical Therapy Modalities, Exercise, Electrical Stimulation Therapy, Bandages
Brief summary
Objective: Compare the benefits of Kinesio Taping and Inhibitory Treatment Techniques for Cervical, Thoracic and Lumbar Spine in Patients with Fibromyalgia Syndrome (FMS). Study Design: A single-blind randomized controlled trial was conducted on patients with FMS. Setting: Clinical setting. Methods: Sixty-four subjects with FMS were randomly assigned to an experimental group receiving kinesio taping and inhibitory treatment techniques, or to a control group for exercises and electrical stimulation therapy.
Interventions
OTHERKinesio Taping and Inhibitory Treatment Techniques
Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles Inhibitory Treatment Techniques: * Release Technique of the trapezius muscle. * Release Technique for scalene muscles. * Technique suboccipital inhibition. * Technique hands crossed for induction dorsal superficial fascia.
OTHERExercise and Electrical Stimulation Therapy
Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
Sponsors
Universidad de Almeria
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed Fibromyalgia Syndrome. * Limitation of usual activities due to pain on at least 1 day in the previous 30 days. * Agreement to attend evening therapy sessions. * Non-practice of regular physical activity.
Exclusion criteria
* A history of surgery. * The presence of comorbid conditions (e.g., morbid obesity, inflammatory diseases, irritable bowel syndrome and interstitial cystitis). * A history of whiplash injury. * Severe physical disability. * uncontrolled endocrine disorders (e.g., hyperthyroidism, diabetes); 6) illness (e.g., schizophrenia or substance abuse). * The use of medication other than as-needed analgesics (excluding long-term narcotics). * Malignancy. * Psychiatric disorders. * A score of ≥ 9 points in the Beck depression inventory.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain Intensity | Changes from Baseline, and 10 weeks | A 10-point Numerical Pain Scale (0: no pain, 10: maximum pain) assesses the intensity of pain. |
Secondary
| Measure | Time frame |
|---|---|
| Pittsburgh Quality of Sleep Questionnaire | Changes from Baseline, and 10 weeks |
| Beck Inventory for Depression | Changes from Baseline, and 10 weeks |
| Fibromyalgia Impact Questionnaire (FIQ) | Changes from Baseline, and 10 weeks |
| Hospital Anxiety Depression Scale (HADS) | Changes from Baseline, and 10 weeks |
| State-Trait Anxiety Inventory (STAI) | Changes from Baseline, and 10 weeks |
| McGill Pain Questionnaire | Changes from Baseline, and 10 weeks |
| Quality of Life (SF-36) | Changes from Baseline, and 10 weeks |
| Pain Pressure | Changes from Baseline, and 10 weeks |
| Schöber Test | Changes from Baseline, and 10 weeks |
| Widespread pain index | Changes from Baseline, and 10 weeks |
| Symptom severity score | Changes from Baseline, and 10 weeks |
| Measurement Finger-Floor | symptom severity scale |
| Fatigue Impact Scale | Changes from Baseline, and 10 weeks |
Countries
Spain
Outcome results
None listed